Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Clomipramine Induced Neuroleptic Malignant Syndrome and Pyrexia of Unknown Origin
BMJ 329:1333-1335, Haddow,A.M.,et al, 2004
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
Epileptic Seizures in Patients with Acute Catatonic Syndrome
JNNP 57:1419-1422, Primavera,A.,et al, 1994
The Nondystrophic Myotonias
In Myology, McGraw-Hill, 2nd Ed, Ch49, p1291-13024., Rudel,R.,et al, 1994
Hyperthermia and Heatstroke
Hospital Practice 29:65-68, 73, 78-80994., Simon,H.B., 1994
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Controlled-Release Delivery of L-Dopa Associated with Nonfatal Hyperthermia, Rigidity, and Autonomic Dysfunction
Neurol 41:942-943, Cunningham,M.A.,et al, 1991
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Neuroleptic Malignant Syndrome:Review and Analysis of 115 Cases
Biol Psychiatry 22:1004-1020, Addonizio,G.,et al, 1987
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Sweet Syndrome
Stat Pearls www.ncbi.nlm.gov, Sept, Goyal,V.P. & Holmes,H, 2022
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients with Anticoagulation-Related Intracerebral Hemorrhage
JAMA 313:824-836, Kuramatsu, J.B.,et al, 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins and Chemical Agents, Mescaline, LSD, and Psilocybin
Adams & Victors Principles of Neurology Chp 43. pg 1215, Ropper, A.H.,et al, 2014
Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report
NEJM 368:2495-2509, Kauffman, C.,et al, 2013
Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma
Neurol 80:574-580, Krueger, D.,et al, 2013
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Plasmablastic Lymphoma after Standard-Dose Temozolomide for Newly Diagnosed Glioblastoma
Neurol 81:93-94, Clark, S.,et al, 2013
Acute Symptomatic Seizures
The Neurologist 18:109-119, Beleza,P., 2012
Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
A 31-Year-Old Woman with a Transformed Low-Grade Glioma
JAMA 303:967-976, Warnke,P.C., 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Prior Antiplatelet Use Dose Not Affect Hemorrhage Growth or Outcome After ICH
Neurol 72:1397-1402,1376, Sansing,L.H.,et al, 2009
CNS Complications of Radiotherapy and Chemotherapy
Lancet 374:1639-1651, Soussain,C.,et al, 2009
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008